Which feature best distinguishes the bronchodilator effect of long-acting beta-2 agonists (LABAs) from that of long-acting muscarinic antagonists (LAMAs)?

Explanation

## Distinguishing LABAs from LAMAs: Mechanism of Action ### Key Concept **Key Point:** The question asks which feature **best distinguishes** the bronchodilator effect of LABAs from LAMAs. The most fundamental and textbook-supported distinguishing feature is their **mechanism of action** — specifically, LABAs act via increased intracellular cAMP, while LAMAs act via muscarinic receptor blockade. | Feature | LABAs (e.g., salmeterol, formoterol) | LAMAs (e.g., tiotropium, aclidinium) | |---------|---------------------------------------|---------------------------------------| | **Receptor target** | β₂-adrenergic (Gs-coupled) | M₃ muscarinic (Gq-coupled) | | **Intracellular pathway** | ↑ cAMP → PKA activation → smooth muscle relaxation | Blocks ACh-mediated bronchoconstriction → ↓ IP₃/DAG → ↓ Ca²⁺ mobilization | | **Onset** | 5–15 min (formoterol); 15–30 min (salmeterol) | 30–60 min | | **Duration** | 12–24 hours | 12–24 hours | | **Mucus effect** | Minimal/variable | Modest reduction via M₃ blockade on glands | ### Why Option A is Correct **Option A — "Mechanism via increased intracellular cAMP and smooth muscle relaxation"** — is the best distinguishing feature because: - This pathway is **unique to LABAs** (β₂-agonist → Gs → adenylyl cyclase → ↑ cAMP → PKA → phosphorylation of myosin light chain kinase → smooth muscle relaxation). - LAMAs do **not** increase cAMP; they block M₃ muscarinic receptors to prevent ACh-mediated bronchoconstriction via a completely different pathway. - This mechanistic distinction is the **primary pharmacological differentiator** between the two drug classes (KD Tripathi, 8th ed., Ch. 16 & 27). ### Why Other Options Are Incorrect - **Option B (Onset 5–15 min):** This applies to fast-acting LABAs like formoterol, but is not a class-wide distinguishing feature of all LABAs vs. LAMAs. - **Option C (Duration >12 hours):** Both LABAs and LAMAs share a duration of 12–24 hours; this does **not** distinguish between them. - **Option D (Mucus hypersecretion and airway remodelling):** While LAMAs have some advantage in reducing mucus via M₃ blockade on glands, the claim that LAMAs reduce airway remodelling is not strongly evidence-based in standard pharmacology textbooks (KD Tripathi, Harrison). Furthermore, the claim that LABAs increase mucus in asthma is overstated and not a reliable class effect. ### Clinical Pearl **Mnemonic:** LABAs = **cAMP** (β₂ → Gs → ↑cAMP); LAMAs = **block ACh** (M₃ antagonism). The mechanism is the clearest, most textbook-supported distinction between these two drug classes. [cite: KD Tripathi 8e Ch 16, 27; Harrison's Principles of Internal Medicine 21e]